Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-10

  Yu, Yanlin ^a   Zeng, Pingyao ^b   Xiong, Jingbo ^c   Liu, Ziyang ^a   Berger, Shelley L ^b   Merlino, Glenn ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLATION OF HISTONE H3 LYSINE 9 PROTEIN; EZRIN; HISTONE H3; SHORT HAIRPIN RNA; TRICHOSTATIN A; TRIMETHYLATION OF HISTONE 3 LYSINE 4 PROTEIN; UNCLASSIFIED DRUG; CYTOSKELETON PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DNA HISTONE INTERACTION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE LOCUS; GENE TARGETING; HUMAN; HUMAN CELL; MALE; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOSOME; NUCLEOTIDE SEQUENCE; PROMOTER REGION; RHABDOMYOSARCOMA; SARCOMA CELL; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; METABOLISM; METHYLATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; METHYLATION; MICE; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; RHABDOMYOSARCOMA;

EID: 77958612597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012710     Document Type: Article

References (57)

1. Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100: 57-70.
2. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8): 789-799.
3. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8): 563-572.
4. Curto M, McClatchey AI (2004) Ezrin.a metastatic detERMinant? Cancer Cell 5(2): 113-114.
5. McClatchey AI (2003) Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer 3(11): 877-883.
6. Geiger KD, Stoldt P, Schlote W, Derouiche A (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 157(6): 1785-1793.
7. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, et al. (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10: 175-181.
8. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, et al. (2001) Metastasisassociated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61: 3750-3759.
9. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, et al. (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2): 182-186.
10. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M (2005) The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7(3): R365-373.
11. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, et al. (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61: 1569-1577.
12. Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258(2): 395-400.
13. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, et al. (2006) Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 66(7): 3629-3638.
14. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O (2005) Ezrin in primary cutaneous melanoma. Mod Pathol 18(4): 503-510. Erratum in: Mod Pathol. 2005; 18(6): 872.
15. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, et al. (2006) Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 281(40): 29938-29948.
16. Louvet-Vallee S (2000) ERM proteins: from cellular architecture to cell signaling. Biol Cell 92: 305-316.
17. Bretscher A, Edwards K, Fehon RG (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586-599.
18. Gautreau A, Louvard D, Arpin M (2002) ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 14: 104-109.
19. Shiue H, Musch MW, Wang Y, Chang EB, Turner JR (2005) Akt2 phosphorylates ezrin to trigger NHE3 translocation and activation. J Biol Chem 280: 1688-1695.
20. Srivastava J, Elliott BE, Louvard D, Arpin M (2005) Src-dependent ezrin phosphorylation in adhesion-mediated signaling. Mol Biol Cell 16: 1481-1490.
21. Yu Y, Davicioni E, Triche TJ, Merlino G (2006) The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 66(4): 1982-1989.
22. Gao SY, Li EM, Cui L, Lu XF, Meng LY, et al. (2009) Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J Biol Chem 284(12): 7995-8004.
23. Felsenfeld G (1992) Chromatin as an essential part of the transcriptional mechanism. Nature 355(6357): 219-224.
24. Mellor J (2006) Dynamic nucleosomes and gene transcription. Trends Genet 22(6): 320-329.
25. Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33(Suppl): 245-254.
26. Grewal SI, Moazed D (2003) Heterochromatin and epigenetic control of gene expression. Science 301(5634): 798-802.
27. Fahrner JA, Eguchi S, Herman JG, Baylin SB (2002) Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62(24): 7213-7218.
28. Fahrner JA, Baylin SB (2003) Heterochromatin: stable and unstable invasions at home and abroad. Genes Dev 17(15): 1805-1812.
29. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16(1): 6-21.
30. Karpf AR, Jones DA (2002) Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21(35): 5496-5503.
31. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9): 769-784.
32. Momparler RL (2005) Epigenetic therapy of cancer with 5-aza-29-deoxycytidine (decitabine). Semin Oncol 32(5): 443-451.
33. Feinberg AP (2004) The epigenetics of cancer etiology. Semin Cancer Biol 14(6): 427-432.
34. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4(2): 143-153.
35. Jones, PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
36. Martin TA, Harrison G, Mansel RE, Jiang WG (2003) The role of the CD44/ ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46(2): 165-186.
37. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16(23): 3074-3086.
38. Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, et al. (1998) Ezrin/ radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140(4): 885-895.
39. Hirao M, Sato N, Kondo T, Yonemura S, Monden M, et al. (1996) Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol 135(1): 37-51.
40. Mangeat P, Roy C, Martin M (1999) ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9(5): 187-192.
41. Schmitz AA, Govek EE, Bottner B, Van Aelst L (2000) Rho GTPases: signaling, migration, and invasion. Exp Cell Res 261: 1-12.
42. Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M (1997) Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol 138: 423-434.
43. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768-771.
44. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1): 37-50.
45. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196.
46. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1): 103-107.
47. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, et al. (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443.
48. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, et al. (2008) Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 68(8): 2736-2744.
49. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, et al. (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66(13): 6546-6552.
50. Blagosklonny MV (2005) Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 12(6): 592-602.
51. Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5(1): 13-7.
52. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, et al. (2005) Epigenetic upregulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 65(5): 1800-1807.
53. Ateeq B, Unterberger A, Szyf M, Rabbani SA (2008) Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10(3): 266-278.
54. Pulukuri SM, Estes N, Patel J, Rao JS (2007) Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res 67(3): 930-939.
55. Jun HJ, Woolfenden S, Coven S, Lane K, Bronson R, et al. (2009) Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res 69(6): 2180-2184.
56. Yu Y, Merlino G (2002) Constitutive c-Met Signaling through a Nonautocrine Mechanism Promotes Metastasis in a Transgenic Transplantation Model. Cancer Res 62: 2951-2956.
57. Li L, Dahiya R (2002) MethPrimer: designing primers for methylation RCRs. Bioinformatics 18: 1427-1431.